Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned a consensus recommendation of “Hold” from the fifteen analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $37.23.

A number of research analysts recently weighed in on HIMS shares. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Citigroup increased their target price on Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a research report on Tuesday, February 25th. Bank of America increased their price objective on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research report on Thursday, February 20th. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Truist Financial raised their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 78,127 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the completion of the transaction, the chief executive officer now directly owns 109,956 shares of the company’s stock, valued at approximately $3,256,896.72. This represents a 41.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,062,011 shares of company stock valued at $36,892,724 over the last ninety days. Insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in HIMS. Crewe Advisors LLC purchased a new position in Hims & Hers Health in the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. grew its position in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its position in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 1.2 %

HIMS stock opened at $40.96 on Friday. Hims & Hers Health has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market cap of $9.10 billion, a price-to-earnings ratio of 93.08 and a beta of 1.35. The business has a 50 day moving average price of $37.34 and a two-hundred day moving average price of $27.27.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities research analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.